Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07099989 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetics of Zelquistinel in Fasted or Fed State

A Phase 1 study of Healthy Volunteers in Fed and Fasted State, sponsored by Syndeio Biosciences.

Active
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT07099989 is a Phase 1 study of Healthy Volunteers in Fed and Fasted State that is active but no longer recruiting, run by Syndeio Biosciences. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07099989, a Phase 1 study of Healthy Volunteers in Fed and Fasted State, is active but no longer recruiting, sponsored by Syndeio Biosciences.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this study is to assess the effect of food on the rate and extent of absorption of a single dose of Zelquistinel 3 mg or 10 mg oral tablets tablets in healthy adult volunteers.

Interventions

  • DRUG Zelquistinel 3 mg
  • DRUG Zelquistinel 10 mg

Study Locations (1)

Kansas

  • Dr. Vince Clinical Research - Overland Park

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2025-07-24
Est. Completion 2026-07
Phase Phase 1

Sponsor

Syndeio Biosciences

7 total trials

What the Registry Record Tells You About NCT07099989

The ClinicalTrials.gov registry entry for NCT07099989 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndeio Biosciences, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers in Fed and Fasted State appearing as the primary indexed condition, and to 2 interventions - of which Zelquistinel 3 mg is the first listed.

NCT07099989 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT07099989 about?

NCT07099989 is a clinical study titled "Pharmacokinetics of Zelquistinel in Fasted or Fed State". The primary purpose of this study is to assess the effect of food on the rate and extent of absorption of a single dose of Zelquistinel 3 mg or 10 mg oral tablets tablets in healthy adult volunteers.

What is the current status of trial NCT07099989?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-07-24. Estimated completion is 2026-07.

What conditions does trial NCT07099989 study?

This clinical trial studies the following conditions: Healthy Volunteers in Fed and Fasted State.

What interventions are being tested in trial NCT07099989?

The interventions under investigation include: Zelquistinel 3 mg (DRUG), Zelquistinel 10 mg (DRUG).

Who is sponsoring clinical trial NCT07099989?

This trial is sponsored by Syndeio Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07099989 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.